CD8A and glioblastoma: Advanced AI-driven treatment options will hopefully continue to gain ground in the landscape of gliomas as well; similarly in 2024, a study reported a new ML-based method to identify cell fate determinants (CFD) via GBM cell reprogramming into induced antigen-presenting cells (iDC-APCs) with functions similar to natural dendritic cells (DCs), capable of priming CD8+ T-cells and enhancing antitumor immunity [197].